https://www.taxtmi.com/article/detailed?id=16691 Pharmaceutical trademark protection does not extend to common prefixes derived from an International Non-Proprietary Name or active ingredient, where those elements are descriptive and available for common use in the trade. In assessing deceptive similarity, the analysis must focus on the distinctive portions of the competing marks, and not on shared INN-based elements that are publici juris. A final finding of trademark infringement after trial requires evidence establishing a legally sustainable likelihood of confusion. Visual comparison alone is insufficient at the adjudicatory stage. en-us Fri, 19 Jun 2026 08:25:03 +0530 Fri, 19 Jun 2026 08:25:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/article/detailed?id=16691 Pharmaceutical trademark protection does not extend to common prefixes derived from an International Non-Proprietary Name or active ingredient, where those elements are descriptive and available for common use in the trade. In assessing deceptive similarity, the analysis must focus on the distinctive portions of the competing marks, and not on shared INN-based elements that are publici juris. A final finding of trademark infringement after trial requires evidence establishing a legally sustainable likelihood of confusion. Visual comparison alone is insufficient at the adjudicatory stage. Articles Other Topics Fri, 19 Jun 2026 08:25:03 +0530 https://www.taxtmi.com/article/detailed?id=16691